Peripheral Nerve Stimulation for Prognostic and Diagnostic Biomarker Identification in Disorders of Consciousness (MICRO-DOC)

August 22, 2025 updated by: Fondazione Don Carlo Gnocchi Onlus

Microneurography and Microneurostimulation for Prognosis and Rehabilitation of Disorders of Consciousness

This observational study aims to integrate anamnestic, clinical, and innovative neurophysiological data to assess their impact on the diagnosis and prognosis of patients with Disorders of Consciousness. The main questions it aims to answer are:

  • Is it possible to identify biomarkers with high diagnostic relevance for distinguishing subcategories of patients with Disorders of Consciousness?
  • Can biomarkers with potential medium- and long-term prognostic value be identified for each category of patients with Disorders of Consciousness?

Participants will undergo an EEG examination during near-nerve stimulation of the median nerve. Clinical and anamnestic data will also be recorded and collected at follow-up.

Study Overview

Detailed Description

At the enrollment of each patient with Disorders of Consciousness, demographic, anamnestic, and clinical data are prospectively collected. The etiology is categorized as traumatic, anoxic, hemorrhagic, or ischemic. The lesion side is defined according to the latest CT scans from the acute phase and is grouped as left, right, and bilateral. All patients undergo a standard neurophysiological evaluation, and the level of consciousness is assessed using the CRS-R scale following international guidelines. It is repeated to confirm the clinical status of the patient, and a reduction of sedation is performed if deemed safe by the physician. Two months after admission to the IRU, the neurophysiological and consciousness assessments are repeated.

In addition to clinical and standard neurophysiological evaluations, two types of SSEPs are acquired during continuous EEG recording through both Surface Cutaneous Stimulation (SCS) and Near-Nerve Stimulation (NNS) of the median nerve. EEG signals are collected using a 61-channel cap with a sampling rate of 512 Hz.

The electrical stimulation is applied over the median nerve proximally to the wrist, and the stimulation side is chosen contralaterally to the less affected hemisphere. Superficial bipolar electrodes are used for SCS, whereas a microneedle with 1 MΩ of impedance is inserted under the skin for NNS. The electrical pulse of 0.2 ms is delivered at a rate of 1 Hz in two sets of 50 repetitions. The stimulation amplitude is chosen as the minimum value able to generate a response only in sensory or sensory-motor fibers for NNS and SCS, respectively. The only sensory activation in NNS is preferred to minimize the influence of motor twitches on brain responses. For SCS, due to the difficulty of exclusively stimulating sensory fibers, the amplitude is set as the minimal value required to elicit both sensory and motor activation.

To monitor the stimulated fibers, the peripheral pathway of the median nerve is recorded. In particular, surface electrodes are positioned on the three fingers innervated by the median nerve for the acquisition of Sensory Nerve Action Potential (SNAP) and on the palm proximally to the motor twitch for the acquisition of Compound Motor Action Potential (CMAP). This information is essential in patients with DoC for different reasons:

i) Identifying the proximity to the median nerve, a crucial step due to the unresponsiveness and lack of cooperation of this population.ii) Identifying the type of active fibers.iii) Monitoring feedback to confirm the accurate placement of the microelectrode.

Whenever the minimum amplitude evokes a CMAP/SNAP, the related amplitude is selected for SCS/NNS. The device automatically extracts the mean values of amplitude and latency of CMAP/SNAP during the experimental session.

Study Type

Observational

Enrollment (Actual)

28

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • FI
      • Florence, FI, Italy, 50143
        • IRCCS Fondazione Don Carlo Gnocchi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who were admitted with a Disorder of Consciousness to the Intensive Rehabilitation Unit (IRU) of Fondazione Don Carlo Gnocchi (Florence).

Description

Inclusion Criteria:

  • Age > 18 years, both sexes;
  • Severe acquired brain injury (regardless of etiology);
  • Patients with severe alteration of consciousness state due to severe acquired brain injury of various etiologies (Cardiac Arrest, Traumatic Brain Injury, Cerebral Ischemia or Hemorrhage);
  • Informed consent signature by family member/caregiver/legal guardian.

Exclusion Criteria:

  • Time since the acute event greater than 3 months;
  • Previous neurological diseases;
  • Previous acute brain injuries, psychiatric disorders, neurodegenerative diseases, neoplasms, severe systemic diseases;
  • Modified Barthel Index pre-event < 50;
  • Unstable medical conditions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with Disorders of Consciousness admitted to the Intensive Rehabilitation Unit

Patients admitted with a Disorder of Consciousness to the Intensive Rehabilitation Unit (IRU) of Fondazione Don Carlo Gnocchi (Florence).

  • Age ≥ 18 years, both sexes;
  • Severe Acquired Brain Injury (ABI), regardless of etiology;
  • Patients with a severe alteration of consciousness due to severe ABI of various etiologies, including Cardiac Arrest, Traumatic Brain Injury, Cerebral Ischemia, or Hemorrhage;
  • Signed informed consent provided by a family member, caregiver, or legal guardian.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of Neurophysiological Diagnostic Biomarkers in Disorders of Consciousness
Time Frame: From enrollment to the baseline experimental session (within 7 days from enrollment)
Quantification of the Agreement Between Newly Proposed Neurophysiological Markers From Near-Nerve Stimulation Examinations and Disorders of Consciousness Classification Based on the Coma Recovery Scale-Revised (UWS, MCS-, MCS+)
From enrollment to the baseline experimental session (within 7 days from enrollment)
Identification of Neurophysiological Prognostic Biomarkers in Disorders of Consciousness
Time Frame: From enrollment to the end of follow up at 6-months from baseline assessment
Quantification of Prognostic Prediction Accuracy of Newly Proposed Neurophysiological Markers From Near-Nerve Stimulation in Classifying Disorders of Consciousness Based on the Coma Recovery Scale - Revised (UWS, MCS-, MCS+, EMCS)
From enrollment to the end of follow up at 6-months from baseline assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 21, 2022

Primary Completion (Actual)

March 28, 2025

Study Completion (Actual)

March 28, 2025

Study Registration Dates

First Submitted

February 17, 2025

First Submitted That Met QC Criteria

February 24, 2025

First Posted (Actual)

February 25, 2025

Study Record Updates

Last Update Posted (Actual)

August 24, 2025

Last Update Submitted That Met QC Criteria

August 22, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Upon publication of results, anonymized data and analysis code will be shared to ensure reproducibility. Zenodo and GitHub repositories will be created.

IPD Sharing Time Frame

Upon publication of results

IPD Sharing Access Criteria

Data and code will be available for research purposes upon request to authors.

IPD Sharing Supporting Information Type

  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disorders of Consciousness Due to Severe Brain Injury

Subscribe